A first-in-man clinical trial of once weekly subcutaneous injection formulation of exenatide (FT228) in healthy volunteers
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 03 Jan 2017
At a glance
- Drugs Exenatide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; First in man
- 03 Jan 2017 This trial was planned by Flamel Technologies. The company has completed cross-border merger and became Avadel Pharmaceuticals plc, according to a Flamel Technologies media release.
- 24 Dec 2015 New trial record
- 22 Dec 2015 Interim results published in a Flamel Technologies media release.